Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
May 01, 2024 06:25 ET
|
G1 Therapeutics
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
Copenhagen Infrastructure Partners secures two offshore wind feasibility licences in Australia and launches new platform company
May 01, 2024 04:00 ET
|
Copenhagen Infrastructure Partners
CIP secures two offshore wind feasibility licences in Australia and launches new platform company
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024 09:01 ET
|
ARS Pharmaceuticals, Inc.
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat...
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
April 29, 2024 09:45 ET
|
Elevai Labs Inc.
Elevai Labs Releases Global Distribution Partnership Overview: Contracts Secure $11.5M Top Line Revenue Boost
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Adeia Enters into Multi-year IP License Renewal with Altimedia
April 23, 2024 08:30 ET
|
Adeia Inc.
SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), a company known for its groundbreaking innovations in entertainment experiences, has announced today that Altimedia, a...
Adeia, 미디어 플랫폼 기업인 Altimedia와 IP 라이선스 계약 다년 연장 합의
April 23, 2024 08:30 ET
|
Adeia Inc.
미국 캘리포니아주 산호세, April 23, 2024 (GLOBE NEWSWIRE) -- 엔터테인먼트 경험의 새로운 혁신을 제시하는 Adeia Inc. (아데이아) (나스닥: ADEA)는 첨단 미디어 서비스 관리 솔루션 기업인 Altimedia (알티미디어)가 Adeia의 미디어 부문 지적재산권(IP) 포트폴리오에 대한 다년 간의 라이선스 계약을...
Metasphere Labs Inc. Unveils Bitcoin-Based Identity System, and Enters Exclusive Licensing Talks with Bot Ventures Inc.
April 23, 2024 07:30 ET
|
Metasphere Labs Inc.
VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is...